Sign in Subscribe

Alex Chompff

Cytokines May Modulate Checkpoint Inhibitor Response in MSI-H CRC

Skip to content The CRC Digest ◇ RESEARCH Cytokines May Modulate Checkpoint Inhibitor Response in MSI-H CRC A review highlights how cytokines can critically modulate immune checkpoint inhibitor effectiveness in mismatch repair-deficient/microsatellite instability-high colorectal cancer by influencing checkpoint expression and shaping the tumor microenvironment. (Critical Reviews in Oncology/Hematology) This

Diet and Tissue Aging Study Offers Clues to Early-Onset CRC Rise

Skip to content The CRC Digest ◇ RESEARCH Diet and Tissue Aging Study Offers Clues to Early-Onset CRC Rise Ultra-processed food intake may contribute to rising early-onset CRC incidence through accelerated epigenetic aging of colorectal tissues, according to a study of 106 participants. (JNCI Cancer Spectrum) This content is informational only

National Database Analysis Examines Post-Pandemic Cancer Screening Patterns

Skip to content The CRC Digest ▪ SCREENING National Database Analysis Examines Post-Pandemic Cancer Screening Patterns Researchers analyzed National Cancer Database records from 2010 to 2023 to compare predicted versus observed incidence rates and late-stage disease proportions for screenable cancers including colorectal cancer following the COVID-19 pandemic screening decline. (Journal of

Cost-Effectiveness Analysis Compares Immunotherapy Options for MSI-H/dMMR mCRC

Skip to content The CRC Digest ▸ TREATMENT Cost-Effectiveness Analysis Compares Immunotherapy Options for MSI-H/dMMR mCRC A U.S. healthcare payer analysis evaluated nivolumab plus ipilimumab versus pembrolizumab and chemotherapy as first-line treatment for the 4-5% of metastatic colorectal cancers that are microsatellite instability-high or mismatch repair deficient. (Advances in

KRAS Mutations Shape Immunosuppressive Tumor Environment

Skip to content The CRC Digest ◇ RESEARCH KRAS Mutations Shape Immunosuppressive Tumor Environment A review describes how KRAS mutations—present in approximately 52% of colorectal cancers—actively create an immunosuppressive tumor microenvironment, presenting a major barrier to both targeted therapy and immunotherapy. (Frontiers in Oncology) This content is informational only

Ultra-Processed Foods Linked to Accelerated Aging in Colorectal Tissue

Skip to content The CRC Digest ◇ RESEARCH Ultra-Processed Foods Linked to Accelerated Aging in Colorectal Tissue A study of 106 participants found that higher intake of ultra-processed foods was significantly associated with accelerated epigenetic aging in normal colorectal tissues, a finding that may help explain rising early-onset CRC rates. (JNCI

CRC Research Update — September 08, 2026

Today's colorectal cancer research highlights

Meta-Analysis Links Metabolic Liver Disease to Early-Onset Advanced Colorectal Neoplasia

Skip to content The CRC Digest ◇ RESEARCH Meta-Analysis Links Metabolic Liver Disease to Early-Onset Advanced Colorectal Neoplasia Systematic review and meta-analysis of cohort studies quantified the association between metabolic dysfunction-associated steatotic liver disease and early-onset advanced colorectal neoplasia, informing risk stratification. (J Gastrointest Oncol) This content is informational only and

Chinese Expert Consensus Establishes Evaluation Standards for AI in Colorectal Cancer

Skip to content The CRC Digest ● REGULATORY Chinese Expert Consensus Establishes Evaluation Standards for AI in Colorectal Cancer (Zhonghua Wei Chang Wai Ke Za Zhi) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

Single-Institution Experience with Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Metastases

Skip to content The CRC Digest ▸ TREATMENT Single-Institution Experience with Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Metastases Retrospective study (2009–2024) evaluated cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with colorectal peritoneal metastases. (Radiol Oncol) This content is informational only and does not constitute medical advice. Always